ENBIOSIS IS NOW OFFICIALLY THE FIRST CLINICALLY PROVEN AI-BASED SOLUTION FOR GUT HEALTH
Microbiome-based Approach On IBS
Over the past decade extensive research has proved that the biological diversity of the gut microbiome and a disruption in the balance of the ecosystem (dysbiosis) play an important role in the pathogenesis of gut diseases.
At ENBIOSIS Biotechnology, we analyze the gut microbiome using artificial intelligence technologies and recommend micro and macronutrients that can modulate the microbiome and drive it towards the target state. We aim to improve the gut microbiome profile by selectively feeding the gut bacteria with the nutrients specific to the individual microbiome needs.
IBS CLINICAL STUDY
Irritable bowel syndrome (IBS), also known as spastic colon, is a functional rather than a structural disorder with a multifactorial pathogenesis. IBS significantly lowers the quality of life of the affected individuals.
IBS is one of the most common chronic functional bowel disorders in adults. 11% of the world’s population is estimated to suffer from IBS. This rate varies between 1.1% and 45.0% on a country-by-country basis.
Our clinical study demonstrated a success rate of 78% on IBS. It is the first and only successful IBS management option that utilized microbiome-specific personalized nutrition recommendations.
CHRONIC CONSTIPATION CLINICAL STUDY
Chronic constipation is a condition in which a person has infrequent bowel movements or passes hard stools. It can cause discomfort, bloating, and abdominal pain. While many people suffering from chronic constipation experience it for some time, the majority suffers from this problem for a long time and looks for different alternatives.
This gut problem is very common with a global prevalence of 15%, which can increase by around 30% in the elderly population.
Our clinical study demonstrated a success rate of 83% on chronic constipation. Microbiome modulation through personalized nutrition is an alternative way to deal with constipation.